 LONDON, Jan. 27, 2022 GLOBE NEWSWIRE -- Freeline Therapeutics Holdings plc Nasdaq: FRLN the Company or Freeline, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposiumTM, a research conference dedicated to lysosomal storage diseases, taking place February 7 11, 2022 in San Diego, California. The presentations will include updated data from the Companys ongoing Phase 12 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 12 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1. 